4 terminated. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 4 |
| Phase 2 | 2 | Terminated 2 |
Follow Drug Evaluation: new trials by email Literature Review of Drug Evaluation trials Research Report on Drug Evaluation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) ZN-d5 ZN-c3, ZN-c3 - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Terminated | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 40 | 2022-12-01 | 2024-09-19 |
| First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML ETH-155008 - NHL, Leukemia | Phase 1 | Terminated | Shengke Pharmaceuticals Pty Ltd | 9 | 2021-06-29 | 2023-10-11 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects AZD6615, Placebo - Dyslipidemia | Phase 1 | Terminated | AstraZeneca | 24 | 2019-07-24 | 2020-12-14 |
| Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers ATG002 (study drug) - Diabetic Foot Ulcers | Phase 1 / Phase 2 | Terminated | CoMentis | 48 | 2006-10-01 | 2007-08-09 |
Diabetes Mellitus (1) · Diabetic Foot (1) · Dyslipidemias (1) · Foot Ulcer (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1)
AstraZeneca (1) · CoMentis (1) · K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (1) · Shengke Pharmaceuticals Pty Ltd (1)
United States (3) · Australia (1)
David Han, MD (1) · Henry Hsu, MD (1) · James Zhang (1)